Volume 87 Issue 44 | Web Exclusive
Issue Date: November 2, 2009

Hikal Branches Out

Indian fine chemicals manufacturer sets up contract research arm
Department: Business
Keywords: Indian API, contract research
[+]Enlarge
GETTING STARTED
Acoris adds early-stage hit-to-lead research and kilogram-scale manufacturing to Hikal's contract manufacturing business.
Credit: Acoris
8744bus1a-440
 
GETTING STARTED
Acoris adds early-stage hit-to-lead research and kilogram-scale manufacturing to Hikal's contract manufacturing business.
Credit: Acoris

Despite worries over supply-chain security after incidents of contaminated drugs from Asia last year, most major pharmaceutical companies insist that proven players in India and China will remain a fixture in their active pharmaceutical ingredient (API)-outsourcing strategies. Indian suppliers are particularly well established in the sector, and many had a large presence at CPhI, the pharmaceutical ingredients conference, in Madrid last month.

In fact, the field has become competitive, with firms such as Piramal Healthcare taking positions among the top global contract manufacturers. As in the U.S. and Europe, companies in India are jockeying to offer what they perceive as an ideal spread of services along the drug development continuum from discovery to commercialization.

Hikal, a contract fine chemicals firm with headquarters in Mumbai, is responding to the competition by expanding its services into contract research and kilogram-scale manufacturing, according to Anish Swadi, vice president of business development.

Last year, Hikal launched an independent subsidiary called Acoris Research, in Pune, India, about 140 km from its headquarters. With eight synthetic chemistry labs, an analytical lab, and a kilolab facility operating to the U.S. Food & Drug Administration's current Good Manufacturing Practice standards, Acoris is offering the kind of "hit to lead" research that drug firms traditionally did in-house and that other Indian players such as Dishman Group and Jubilant Organosys now offer as a service, Swadi says.

Although Swadi and his colleagues hope that research contracts will lead to manufacturing deals, he says Hikal elected to run Acoris as a separate corporate entity. "A lot of potential customers may already have manufacturing tie-ins to other contractors, and others are concerned about patent protection," he says. "We wanted to set up a firewall between contract research and manufacturing."

With about 100 employees, Acoris already has 10 projects under way with both large and start-up pharmaceutical companies. It also has a contract with Pittsburgh-based Plextronics to manufacture chemicals for organic light-emitting diodes.

Running two separate businesses reflects concerns among some U.S. and European drug companies about protection of intellectual property in India, Swadi acknowledges. Yet he points out that Hikal has had successes—including contracts with Pfizer, Bayer CropScience, and Alpharma—that should help build the contract research subsidiary.

"Getting Western business is about achieving a level of satisfaction and comfort," Swadi says. "Our track record with big pharma on the manufacturing side will lead us to contracts for Acoris. Our respect for intellectual property rights is tremendous."

According to Enrico Polastro, a consultant with Arthur D. Little in Brussels, Indian suppliers in general have been moving up the value chain. "They are going beyond simply supplying headcount and reactor capacity to also offering value-added services," he says. "You will notice that Indian companies' booths at CPhI have signs that are no longer about products but about a broad range of capabilities."

Hikal, a long-time player in agricultural chemicals, has been pushing to boost its pharmaceuticals business with U.S. and European clients, according to Polastro. He notes that the president of Acoris, R. Helmut Rupp, is a former research executive at Lonza.

Swadi says Acoris plans a second phase of building in Pune to increase both research and kilolab-manufacturing capacities. "Hopefully, the financial environment will improve by next year," he says. "Once we have the orders in hand, we will build phase two."

 
 
 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment